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Background: Cervical cancer is the most common cancer experienced by women worldwide; however, screening
techniques are very effective for reducing the risk of death. The national cervical cancer screening program was
implemented in Taiwan in 1995. The objective of this study was to examine and provide evidence of the cervical
cancer mortality trends for the periods before and after the screening program was implemented.
Methods: Data from 1981 to 2010 of the causes of death registered were obtained from the Department of Health,
Taiwan. Age-standardized mortality rates, age-specific rates, and age-period-cohort models that employed the
sequential method were used to assess temporal changes that occurred between 1981 and 2010, with 1995 used
as the separating year.
Results: The results showed that for both time periods of 1981 to 1995 and 1996 to 2010, age and period had
significant effects, whereas the birth cohort effects were insignificant. For patients between 80 and 84 years of age,
the mortality rate for 1981 to 1995 and 1996 to 2010 was 48.34 and 68.08. The cervical cancer mortality rate for
1996 to 2010 was 1.0 for patients between 75 and 79 years of age and 1.4 for patients between 80 and 84 years of
age compared to that for 1981 to 1995. Regarding the period effect, the mortality trend decreased 2-fold from 1996
to 2010.
Conclusions: The results of this study indicate a decline in cervical cancer mortality trends after the screening
program involving Papanicolaou tests was implemented in 1995. However, the positive effects of the screening
program were not observed in elderly women because of treatment delays during the initial implementation of the
screening program.
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Cervical cancer is the most common and serious gyne-
cologic malignancy worldwide. This finding highlights
the urgent need to significantly increase cancer survival
rates and reduce mortality through screening programs.
Cervical screening methods that involve cytology tests,
the Papanicolaou technique (PT), human papillomavirus
(HPV) tests, and visual inspections of the cervix with 5%
acetic acid (VIA) have been established to reduce the cer-
vical cancer mortality rate by almost 60% in numerous* Correspondence: liawyp@csmu.edu.tw
1Department of Public Health and Institute of Public Health, Chung Shan
Medical University, No. 110 Sec 1 Chien-Kuo N. Road, Taichung City 40201,
Taiwan
Full list of author information is available at the end of the article
© 2013 Su et al.; licensee BioMed Central Ltd.
Commons Attribution License (http://creativec
reproduction in any medium, provided the orcountries [1,2]. National cervical cancer screening pro-
grams have been implemented in many countries through-
out the world, including Australia [3], Nordic countries
(that is, Iceland [4], Scandinavia [5], Finland [6], and
Norway [7]), England [8], France [9], Germany [10],
the U.S. [11], and Canada [12]. Additionally, many recent
studies have shown that the efficacy of screening programs
have increased the survival rate and reduced the mortality
rate of cervical cancer.
According to the World Health Organization (WHO)’s
cervical cancer screening guidelines, screening is defined
as testing all women at risk of cervical cancer, most of
whom will not exhibit symptoms. The objective of screen-
ing is to detect precancerous changes that, if left untreated,This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.biomedcentral.com/1471-2458/13/13can lead to cancer. However, screening is only effective if a
well-organized follow-up and treatment system is also pro-
vided. Women who are found to have abnormalities during
screening require follow-up consultations, diagnosis, and
possibly treatment to prevent the development of cancer
or to treat cancer in the initial stage. Several tests
can be used to screen for cervical cancer. However, the
Papanicolaou smear (Pap cytology) is the only test that
has been applied to large populations and been shown to
reduce the incidence and mortality rate of cervical cancer.
Although VIA, and HPV test have shown potential, to
date, no comparable evidence of their effectiveness exists.
Large-scale studies are still being conducted. Regard-
less of the test used, the key to an effective program
is to target the largest proportion of women at risk with
quality screening and treatment. Organized screening
programs that are designed to reach most women at
risk and managed at a central level are preferable to
opportunistic screening.
The Bureau of Health Promotion of the Department
of Health implemented the screening program in Taiwan
in 1995. Under the screening policy, free annual medical
examinations are provided to all Taiwanese women aged
30 years or older. Women who are sexually active are
strongly advised to undergo a smear test at least once
every 3 years. Women who have been diagnosed with a
sexually transmitted disease, the human immunodefi-
ciency virus, the human papillomavirus, or cervical dys-
plasia, and who have numerous sexual partners, should
undergo testing once every year. The results of a smear
test provide a reference for whether further examina-
tions are necessary. If the test results are unclear regard-
ing pathological changes, women are recommended to
undergo a biopsy. If the biopsy indicates carcinoma in
situ, women will only require a simple operation to fully
cure the disease.
Through a time trend analysis of mortality rates, we
can evidence the efficacy of cervical screening programs.
The age-period-cohort (APC) model is one of the most
common statistical methods. In a previous study [13], a
number of researchers presented the cervical cancer
mortality trends in Taiwan; however, that study analyzed
mortality trends between 1974 and 1992. Therefore, the
aim of this study was to examine the cervical cancer
mortality rates following the implementation of the
screening program, and identify differences that oc-
curred around the time the screening program was
implemented.
Methods
Data from 1981 to 2010 of the causes of death registered
were obtained from the Department of Health, Taiwan.
We selected three variables for sequentially analysis, that
is, age of death, period of death, and the coding ofInternational Classification of Diseases (ICD). To deter-
mine the three factors (age, period, and cohort) for time
trend analysis, we first excluded patients who were aged
19 and under and patients who were aged 85 and
over before separating the participants into 13 groups
of 5 age bands each. Second, we separated 6 aggrega-
tions by 5 years of death for each period group. Fi-
nally, cohort groups were calculated according to age
groups and period groups. Cervical cancer was defined as
malignancies of the endocervix (ICD-9th for 180.0, and
ICD-10th for C53.0), exocervix (ICD-9th for 180.1, and
ICD-10th for C53.1), other specified sites of the cervix
(ICD-9th for 180.8, and ICD-10th for C53.8), and unspeci-
fied sites of the cervix uteri (ICD-9th for 180.9, and
ICD-10th for C53.9).
The APC model that employs the sequential method
[14] is a serial process that comprises two mathematical
steps. First, we modeled the age effect and the period
effect. Then the results are combined for the offset func-
tion to calculate the cohort effect in the second step.
Finally, we also considered the model fit using the spline
smoother function of the sequential method. We choose
the natural spline function for modeling, and used the
Akaike information criterion (AIC) to determine the
appropriate number of knots. All age, period, and cohort
effects were separated into two parts, those for 1981 to
1995 and those for 1996 to 2010. Additionally, we calcu-
lated the period ratios (1996 to 2010/1981 to 1995)
according to age groups. We also determined the age-
standardized mortality rate (ASMR) using the 2000
World Standard Population Report produced by the
WHO as the reference population combined with the
age specific rate for 30 years. All the statistical technics
were conducted using R software.
Results
The ASMRs for cervical cancer from 1981 to 2010 are
shown in Figure 1; the results show a watershed and in-
dicate that the peak of the mortality trend reached 13.5
(per 100,000) in 1991 to 1995. However, the ASMRs
declined by approximately 50% over the 30 years.
Figure 2 shows the age (A, B), period (C, D), and cohort
(E, F) effects of cervical cancer for the two periods of 1981
to 1995 and 1996 to 2010. The results show that age had a
significantly positive effect in each period, and the morta-
lity rates for the oldest age group were 50 (per 100,000)
and 68.1 (per 100,000) for 1981 to 1995 and 1996 to 2010.
The period effects exhibited a contrary trend; that is, the
mortality rate ratios gradually increased after 1981 before
declining 2-fold from 1996 to 2010. No cohort effects
were observed for both periods.
The period ratio based on the age effect of the APC
model is shown in Figure 3. The results show that the



































Figure 1 Age standardized mortality rates of cervical cancer in
1981–2010.
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mented by age. Generally, the influence of the age effects
on mortality rates after 1995 was lower than that before
1995 year. However, an equal level was exhibited by
patients between 75 and 79 years of age, and patients be-
tween 80 and 84 years of age exhibited a ratio of 1.4-fold.
The age specific mortality rates for cervical cancer
according to each age group over 30 years are shown in
Figure 4; the central dashed line denotes the year 1995.
Each trend of mortality rates was similar to the ASMR.
The results show that the peak of each mortality rate
occurred around the dashed line before subsequently
declining. However, the results indicated a lack of time for
older patients between 75 and 79 years of age and 80 and
84 years of age. The age specific mortality rate of patients
between 75 and 79 years of age and patients between 80
and 84 years of age decreased after 1998 until 2003.
Discussion
We conducted separate APC model calculations for the
periods of 1981 to 1995 and 1996 to 2010 to verify the
hypothesis that the cervical screening program influ-
enced the mortality trends after 1995. The results not
only supported the positive effects of the screening
program, but also showed unexpectedly patterns.
First, the ASMR results and the period effects of the
APC model both indicated that cervical cancer mor-
tality trends were reduced after the screening program in-
volving Papanicolaou test was implemented in 1995.
Additionally, many previous studies have reported on the
efficacy of the screening program in Taiwan [15-18]. Se-
cond, the effects of the screening program were not
observed among elderly women.
The differential period ratios for cervical cancer show
a decline in mortality rates for people between 30 and
79 years of age after the implementation of the screeningprogram. By contrast, the risk of mortality caused by the
protectiveness of the screening program was 1.4-fold
higher than that during the periods before the screening
program was implemented among patients between 80
and 84 years of age. These contradictory patterns may in-
dicate a problem. Additionally, the screening rates among
elderly women in Taiwan may be lower, preventing early
diagnosis and treatment, thereby increasing their mortality
rate and reducing their survival rate. However, the answer
to this issue was found in the statistical data obtained
from the Bureau of Health Promotion of the Department
of Health. The data indicated that the screening rates were
55% to 65% for women aged between 30 and 39, 50% to
60% for women aged between 40 and 49, 45% to 55% for
women aged between 50 and 59, 40% to 50% for women
aged between 60 and 69, and 25% to 32% for women aged
70 or more. Thus, the screening rates were lower among
elderly women.
The cervical cancer mortality rate for older age groups
(70+) exhibited an increasing trend before 1995, but not
among younger women. i.e. the mortality risks for
women aged 70 years or more increased annually before
1995; whereas no significant change in mortality trends
was observed among women under 70. Present studies
cannot provide a suitable explanation for this finding.
The reason for these results may be a particular risk fac-
tor directly or indirectly related to age that remains un-
known. However, we still propose some possible reasons
causing this phenomenon for subsequent study valid-
ation. Regarding the phenomenon of multiple births
among women of the post-war generation, a number of
previous studies have suggested that pregnancy at an
excessively early age and excessive pregnancies may be
risk factors for cervical cancer [19-22]. Taiwan experi-
enced a post-World War II baby boom. Beginning in
1947, the birth rate increased from 38.31 to 49.97 by
1951. Consequently, we can infer that women who were
70 to 84 years of age between 1980 and 1995 were of a
reproductive or childbearing age (i.e., 20 to 35 years
of age) from approximately 1930 to 1960. This includes
all women at childbearing age during the post-war
baby boom.
However, the results of numerous previous studies also
support the limited effectiveness of cervical cancer
screening among elderly women [23-27]; one study even
contended that screening elderly women was inefficient
and should be terminated for women aged 65 or older
who have a history of regular negative smears [27]. Con-
sidering this argument, we contend that if screening is
genuinely ineffective among elderly women, then the
mortality rate should remain unaffected. However, this is
completely unreasonable in Taiwan. The pattern of age-
specific mortality rates for each age group shown in
Figure 4 exhibited a declining trend among elderly
Figure 2 Age(A, B), period(C, D), and cohort(E, F) effects of cervical cancer between 1981–1995 and 1996–2010.


























Figure 3 The differential period ratios of cervical cancer form
age effects of age-period-cohort model.
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the screening program may not immediately affect women
between 80 and 84 years of age in Taiwan because of
treatment delays during the initial screening program
implementation stage. Previous studies related to the
effectiveness of screening have considered the prob-
lem of a lead time bias. However, the idea that redu-
cing incidence was the main screening effect that




























Figure 4 The age specific mortality rates of cervical cancer by each aon the notion that no deaths would be caused by a
disease if the disease did not occur. However, the
reduced mortality rate caused by screening is not en-
tirely because of a lower or reduced incidence rate.
Especially when cancer prognosis results are good,
implementing screening may increase the incidence
rate, but it can reduce mortality rates through early
treatment. For example, in Taiwan, a few years after
the screening program was implemented in 1995, the
incidence of cervical cancer increased significantly;
however, the corresponding mortality rate declined
following the implementation of the screening pro-
gram. Thus, the reduced mortality rate for cervical
cancer cannot be mainly attributed to a lower inci-
dence; instead, it was also affected by whether the
Papanicolaou test provided good prognosis results,
thereby increasing the patient survival rate.
In 2006, Lloroa [28] contended that the low cervical
cancer mortality rates were not only the result of the
Papanicolaou test or other screening techniques and
treatment reforms, but could also be attributed to mis-
classifications on death certificates. The study showed
that numerous uterine cancer cases were classified as
“site unspecified.” According to Cuzick and Beral [29,30],
uterine cancers can be classified into three types, that is,
cervical cancer, corpus uteri cancer, and cancer of the















ge group during 30 years.
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UNOS may be caused by the revision of the International
Classification of Diseases (ICD). Therefore, the proportion
of UNOS declines should be considered to examine
changes in cervical cancer mortality. Furthermore, to ob-
tain an accurate calculation for long-term analysis, Lloroa
suggested that the proportion of UNOS and uterine can-
cers should combined to determine cervical cancer mor-
tality rates [28].
However, this assumption and concept do not need to
be considered in this study. Furthermore, the above con-
ditions indicate that the study design included analysis
of long-term trends and more than one version of ICD
codes. In the studies conducted by Lloroa and Levi, the
periods analyzed were 1955 to 1995 and 1960 to 1998,
and they included 4 versions (ICD-7th to 10th) and 5
versions (ICD-6th to 10th) of ICD codes. To the best
of our knowledge, the different versions of ICD codes
were developed through diagnosis and treatment.
Thus, we can infer that the old version may be the
primary cause of the assumption. Based on this con-
dition, we calculated the cervical cancer mortality
trends for 1981 to 2010, but we only included two
versions of ICD codes. However, the death registra-
tion system in Taiwan cited ICD-9th for death certifi-
cates for 1981 to 2008, and ICD-10th for 2008 to the
present. Therefore, the effects of various versions of
ICD codes are the lowest in this study.
The accuracy of cause-of-death coding in Taiwan
appears to vary according to the type of disease[32]. Dis-
agreements between the reviewer and the original coder
included disagreements regarding the nomenclature,
inappropriate judgments of cause relationships, and
incorrect interpretation of the International Rule for
Selecting the Underlying Cause of Death, and Modifying
the Selected Underlying Cause of Death. The cause-
of-death data used in this study was analyzed in 1994
and published in 2000. Therefore, the early cause-
of-death data may influence the accuracy of the study
results; this is the inevitable study limitation.
The quality indicators included the percentage of mor-
phologically verified cases (MV%). The percentage of
death-certificate-only cases (DCO%) between 1980 and
2009 show steady improvements in the quality of Taiwan
Cancer Registry. The MV% increased from 82.4% be-
tween 1980 and 1984 to 89.05% between 2005 and 2009.
The DCO% declined from 28.8% between 1985 and
1989 to 1.4% between 2005 and 2009.
Conclusions
The results of this study support the effectiveness of the
screening program through analysis of the results of the
APC model and other standard statistic techniques. For
both older and younger women in Taiwan, the screeningprogram provided positive effects by reducing mortality
rates; however, it also provided a delayed effect among
elderly women. The reliability of supplementary mea-
sures following screening using Papanicolaou tests may
be significant contributors. However, additional related
studies with demographic analyses of the initial screen-
ing program implementation delay pattern are required
for clarification in future research.
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